Vitamin C and microneedling granulomas: what the case reports show
Clinicians have reported granulomatous reactions after microneedling with multi-ingredient serums. Those reports establish the observed exposures and reactions, with uncertainty about the cause.
Published case reports describe granulomatous skin reactions after microneedling with multi-ingredient products that contained vitamin C. They cannot establish how often the reaction occurs or identify vitamin C alone as its cause. FDA has not reviewed the safety or effectiveness of combining cleared microneedling devices with other products for delivery into the skin.123
The product list matters more than the name on the menu
A practice might say it used “vitamin C,” but a serum can contain several active and inactive ingredients. In a three-person original series, two people had been exposed to the same vitamin C-containing product and the third had a different topical product. Another report describes an exposure that included vitamin C, niacinamide and botanical ingredients. Those are specific records of combined exposures. A headline that assigns the reaction to one ingredient goes beyond what the reports can establish.23
Granulomatous inflammation is a clinical finding. A person who sees persistent bumps cannot establish that finding from a photograph. The cases are valuable because clinicians evaluated the reactions and recorded the products used, which is different from assuming that a new bump follows the same explanation in every patient.23
Read the device and serum records separately
FDA’s consumer guidance distinguishes cleared microneedling uses from combinations with cosmetics, drugs or other products. A device’s clearance for a named skin indication does not review the combined use with a particular serum. Likewise, labeling a serum for topical use does not supply evidence about its use in a microneedling procedure. Each record answers a different question.1
| Detail | Where to find it |
|---|---|
| Device | Device and cartridge from the procedure record or package. |
| Serum or gel | Brand, product name, ingredient list and lot if the practice has it. |
| Exposure | Whether the product was used during the procedure or separately and where it was applied. |
| Skin change | When and where it appeared, how it evolved and whether a clinician assessed it. |
A suspected ingredient and a proven cause are different
A case series can bring attention to a pattern clinicians had reason to investigate. It does not supply the comparison groups that could separate the effects of the device, the serum, its individual ingredients or other exposures. If a clinic offers a different product under the same general ingredient name, the old case cannot identify that product’s risk. It still illustrates why an ingredient list and the exact use belong in the record. Evidence about a topical cosmetic used alone does not fill this gap because it is a different exposure from the combination under discussion.123
Give the clinician the sequence
If a new or persistent reaction is occurring, contact the treating clinician or a dermatologist for assessment. The practice can provide the product list and identify what was used on each area. Keep the timing of the procedure and the later symptoms distinct. These facts allow an evaluation even when the procedure name and serum nickname are ambiguous.23
Before selecting a microneedling provider, ask which part of the offer is the device procedure and which part is a separate product. Request the exact combination’s evidence and the contact who reviews a skin concern. The microneedling recovery guide covers general follow-up, while this decision depends on preserving the actual product record.
Sources
- U.S. Food and Drug Administration. Microneedling Devices: Getting to the Point on Benefits, Risks and Safety. Explains that FDA has not reviewed the safety or effectiveness of combining cleared devices with other products. Accessed .
- JAMA Dermatology / original case series. Facial Allergic Granulomatous Reaction and Systemic Hypersensitivity Associated With Microneedle Therapy for Skin Rejuvenation. Three original cases after microneedling and topical product exposure, including two people exposed to the same vitamin C-containing serum. Accessed .
- PubMed / original research. Treatment-refractory granulomatous reaction to microneedling with transepidermal drug delivery of vitamin C, niacinamide, and botanical extracts. Additional original report identifies a mixed exposure. It does not isolate vitamin C as a causal ingredient. Accessed .